GSK Inks $1.71 Billion Deal with Hansoh Pharma for Global Rights to B7-H3 ADC HS-20093

On December 20, Shanghai Hansoh BioMedical Co., Ltd., a wholly-owned subsidiary of Hansoh Pharmaceutical Group Company Limited, entered into a licensing agreement with GSK. GSK will obtain the exclusive global license (excluding mainland China, Hong Kong, Macao, and Taiwan) for the development, manufacture, and commercialization of HS-20093.

HS-20093 is a novel B7-H3-targeted antibody-drug conjugate (ADC), composed of a fully humanized B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor (TOPOi) payload. It is currently undergoing multiple Phase I and Phase II clinical trials in China for the treatment of lung cancer, sarcoma, head and neck cancer, and other solid tumors.

According to the license agreement and its terms and conditions, Hansoh Bio will receive an upfront payment of $185 million and is eligible to receive milestone payments of up to $1.525 billion upon the achievement of related events for the product. After the commercialization of the product, GSK will also pay tiered royalties on global net sales outside of mainland China, Hong Kong, Macao, and Taiwan.

Just two months ago, Hansoh Pharma granted GSK the exclusive global license (excluding mainland China, Hong Kong, Macao, and Taiwan) for its novel B7-H4-targeted ADC drug HS-20089, with a total transaction value of up to $1.57 billion.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position; for reprinting, please leave a message to the WeChat Official Account backend or send a message, and include the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.